SynDevRx Obtains $602,747 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    One Broadway 14th Floor Cambridge, MA 02142
  • Company Description
    Our mission is to improve human health by developing polymeric prodrugs which deliver MetAP2 inhibitors to diseased tissues. The first two drug candidates we are developing have been previously shown to shrink tumors, inhibit angiogenesis and prevent metastasis in early clinical trials.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for solicitation details, if applicable.
  • M&A Terms
  • Venture Investor

By posting a comment, you agree to our terms and conditions.